(Reuters) – Roche reported on Thursday a 3% decline in its third-quarter turnover, penalized by a sharp drop in sales of products against COVID-19 and by a strong Swiss franc which weighed on his income abroad.
Quarterly sales of the Swiss manufacturer of drugs and diagnostic products came to 14.3 billion Swiss francs (15.1 billion euros), broadly in line with analysts’ estimates.
Roche still expects its sales and adjusted earnings per share to fall in a range between 1% and 5% (“low single-digit”) in 2023, excluding currency effects.
The group, however, expects a less pronounced drop in sales of products against COVID-19, which include screening tests, the treatment Ronapreve as well as the repackaged arthritis drug Actemra.
These sales are expected to decline by around 4.5 billion Swiss francs in 2023 while the group previously forecast a decline of 5 billion.
(Report Ludwig Burger, Written by Friederike Heine, Dagmarah Mackos, edited by Blandine Hénault)
Copyright © 2023 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
